Home-based monitoring for diabetic macular edema treatment

Home Care Monitoring of Visual Acuity and OCT Versus Standard Hospital/Clinic Care Monitoring During Diabetic Macular Edema Management: A Non-inferiority Randomized Clinical Trial

This study is testing if using home-based monitoring tools can help people with diabetic macular edema keep their vision stable while reducing the need for frequent trips to the clinic.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 308 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University (Academic / other)
• Locations: 3 sites (Dongguan, Guangdong and 2 other locations)
• Trial ID: NCT06610747 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the effectiveness of home-based monitoring for patients with diabetic macular edema (DME) compared to traditional hospital-based care. It utilizes portable self-administered OCT devices and visual acuity testers to allow patients to conduct routine monitoring at home, potentially reducing the need for frequent clinic visits. The study aims to determine if this approach can maintain or improve visual acuity outcomes while enhancing patient compliance with treatment schedules. By addressing the barriers associated with regular clinic visits, the trial seeks to improve overall treatment outcomes for DME patients.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with type 1 or type 2 diabetes who are currently using insulin or oral anti-hyperglycemic agents.

Not a fit: Patients with unstable medical conditions or those unable to operate the home monitoring devices may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve treatment adherence and visual outcomes for patients with diabetic macular edema.

How similar studies have performed: Other studies have shown promise in remote monitoring approaches for chronic conditions, suggesting potential success for this novel method in DME management.

Eligibility criteria

Participant-level Criteria:

Inclusion Criteria:

To be eligible, the following inclusion criteria must be met:

* Age of 18 years or older;
* Type 1 or type 2 diabetes mellitus
* Current regular use of insulin for the treatment of diabetes or current regular use of oral anti-hyperglycemia agents for the treatment of diabetes
* Travel time from home to the hospital/clinic within a 2-hour driving distance
* At least one eye meets the study eye criteria listed in Section 2.4
* Ability and willingness to operate the self-administrated visual acuity tester and Home OCT device by themselves or with the help of family after training
* Ability and willingness to provide informed consent

Exclusion Criteria:

An individual is not eligible if any of the following exclusion criteria are present:

* Conditions that would preclude participation in the study, such as unstable medical status including blood pressure, cardiovascular disease, renal disease, and glycemic control as determined by the investigators
* History of systemic anti-VEGF or pro-VEGF treatment within 4 months before randomization. These drugs should not be used during the study;
* In an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied
* Blood pressure \> 180/110 (systolic above 180 or diastolic above 110. If blood pressure is brought below 180/110 by anti-hypertensive treatment, then the individual may be eligible
* History of myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months before enrollment
* For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 2 years. Women who are potential study participants should be questioned about the potential for pregnancy, and the investigator will determine when a pregnancy test is needed
* Currently participating in other clinical trials
* The individual who might move out to an area beyond 2-hour driving distance during the first 12 months of the study

Study eye-level Criteria:

The participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below. Participants can have only one study eye. If both eyes are eligible at the time of enrollment and one of the eyes has never received anti-VEGF treatment, that eye should be included. If both eyes are eligible and have previously received anti-VEGF treatment or both eyes have never received anti-VEGF, then the better-seeing eye will be selected before enrollment. If neither eligible eye is the better-seeing eye, then the investigator and participant will select the study eye by mutual agreement before enrollment.The definition of better-seeing, worse-seeing and same eye is in the followings:

* If the baseline visual acuity letter score in both eyes is 50 (20/100) or better, the better-seeing eye is the eye with better baseline visual acuity (better than that of the fellow eye by 5 letters or more), and the worse-seeing eye is the eye with worse baseline visual acuity (worse than that of the fellow eye by 5 letters or more); if the baseline visual acuity of one eye is within 4 letters of that of the fellow eye, the two eyes are the same and neither eye is the better-seeing eye.
* If the baseline visual acuity letter score in both eyes is \< 50 (20/100), the better-seeing eye is the eye with better baseline visual acuity (better than that of the fellow eye by 10 letters or more), and the worse-seeing eye is the eye with worse baseline visual acuity (worse than that of the fellow eye by 10 letters or more); if the baseline visual acuity of study eye is within 9 letters of that of the fellow eye, the two eyes are the same and neither eye is the better-seeing eye.

The eligibility criteria for a study eye are as follows:

Inclusion Criteria:

* Central-involved DME (central subfield thickness on OCT defined on Heidelberg Spectralis OCT 320 μm or more in men and 305 μm or more in women, or Zeiss Cirrus OCT 305 μm or more in men and 290 μm or more in women, or the equivalent on spectral-domain OCT based on gender specific cutoffs)
* Best corrected visual acuity letter score ≤ 78 (i.e., 20/32 or worse) and ≥ 24 (i.e., 20/320 or better) within seven days of inclusion
* Received no treatment for DME before, or received no anti-VEGF injection for DME within the past 3 months; however, if there is a history of anti-VEGF injections, \<=1 injection in the past year and \<=3 injections over the study participant's lifetime); or, \<=2 monthly injections within the past 3 months and \<=3 injections over the past year, and \<=6 injections over the study participant's lifetime.
* Sufficient media clarity, pupillary dilation, and individual cooperation to allow for adequate fundus photographs and adequate OCT

Exclusion Criteria:

The following exclusions apply to the study eye only (i.e., they may be present for the non-study eye):

* Macular edema due to reasons other than diabetes
* Any history of prior laser, other surgical or corticosteroid treatment for DME (such as focal/grid macular photocoagulation, intravitreal corticosteroids or peribulbar corticosteroids) within the prior 12 months
* History of intravitreal anti-VEGF for an ocular condition other than DME (e.g., choroidal neovascularization, central retinal vein occlusion, PDR) within the prior 6 months or anticipated need in the next 6 months
* Coexisting ocular diseases that might alter visual acuity during the course of the study, such as a retinal vein or artery occlusion, uveitis or other ocular inflammatory diseases, neovascular glaucoma, etc.
* A substantial cataract that, in the investigator's opinion, is likely to be decreasing visual acuity by 3 lines or more. This means that the cataract would be reducing acuity to 20/40 or worse if the eye were otherwise normal
* History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckling, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization
* Uncontrolled glaucoma
* Severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis.

Where this trial is running

Dongguan, Guangdong and 2 other locations

• Dongguan Guangming Ophthalmic Hospital — Dongguan, Guangdong, China (Recruiting)
• The Second Peoples Hospital of Foshan — Foshan, Guangdong, China (Recruiting)
• State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)

Study contacts

• Study coordinator: Yingfeng Zheng, MD, PhD

Conditions Diabetic Macular Edema; Diabetic macular edema; Diabetic retinopathy; Aflibercept; Anti-VEGF; Home care monitoring; Home OCT; Best-corrected visual acuity